caa a22 4500 465789374 CHVBK 20180323112019.0 cr unu---uuuuu 170327e19900201xx s 000 0 eng 10.1007/BF00216919 doi (NATIONALLICENCE)springer-10.1007/BF00216919 Experimental antitumor activity of BMY-28175 a new fermentation derived antitumor agent [Elektronische Daten] [John Schurig, William Rose, Hideo Kamei, Yuji Nishiyama, William Bradner, Dale Stringfellow] Summary: BMY-28175 is a novel antitumor antibiotic produced in fermentation by Actinomadura verrucosospora. The cytotoxic effects of BMY-28175 were determined using murine and human tumor cell lines in vitro. Following 72 hour exposure, the drug had IC50 values 1.5 to 13.5 ng/ml in a microtiter assay. BMY-28175 was evaluated for antitumor activity against several experimental murine and human tumor models. The drug administered ip was active against ip implanted P388 leukemia, L1210 leukemia, B16 melanoma, M109 lung carcinoma, C26 colon carcinoma, M5076 sarcoma and Lewis lung carcinoma. In addition, BMY-28175 administered iv was active against iv implanted P388 and L1210 leukemias. BMY-28175 was active against sc implanted B16 melanoma (increased lifespan and/or inhibition of primary tumor growth) in about 60% of the tests. The growth of sc implanted M109 was inhibited by BMY-28175 in a single experiment. BMY-28175 was also active against the MX-1 human mammary xenograft implanted in the subrenal capsule of nude mice. The optimal dose for BMY-28175 in these various studies ranged from 0.16 μg/kg per injection with consecutive daily (qd1-9) administration, to 51.2 μg/kg with single dose administration. The results of these studies indicate that BMY-28175 is one of the most potent antitumor agents yet observed, with a broad spectrum of activity against tumors of murine and human origin and activity against tumors located distal to the site of drug administration. Kluwer Academic Publishers, 1990 antitumor nationallicence antibiotic nationallicence cytotoxicity nationallicence Schurig John Bristol-Myers Co., Inc., Pharmaceutical Research and Development Division, 06492, Wallingford, CT, USA aut Rose William Bristol-Myers Co., Inc., Pharmaceutical Research and Development Division, 06492, Wallingford, CT, USA aut Kamei Hideo Bristol-Myers Co., Inc., Pharmaceutical Research and Development Division, 06492, Wallingford, CT, USA aut Nishiyama Yuji Bristol-Myers Co., Inc., Pharmaceutical Research and Development Division, 06492, Wallingford, CT, USA aut Bradner William Bristol-Myers Co., Inc., Pharmaceutical Research and Development Division, 06492, Wallingford, CT, USA aut Stringfellow Dale Bristol-Myers Co., Inc., Pharmaceutical Research and Development Division, 06492, Wallingford, CT, USA aut Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 7-15 0167-6997 8:1<7 1990 8 10637 https://doi.org/10.1007/BF00216919 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00216919 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Schurig John Bristol-Myers Co., Inc., Pharmaceutical Research and Development Division, 06492, Wallingford, CT, USA aut NATIONALLICENCE 700 1- Rose William Bristol-Myers Co., Inc., Pharmaceutical Research and Development Division, 06492, Wallingford, CT, USA aut NATIONALLICENCE 700 1- Kamei Hideo Bristol-Myers Co., Inc., Pharmaceutical Research and Development Division, 06492, Wallingford, CT, USA aut NATIONALLICENCE 700 1- Nishiyama Yuji Bristol-Myers Co., Inc., Pharmaceutical Research and Development Division, 06492, Wallingford, CT, USA aut NATIONALLICENCE 700 1- Bradner William Bristol-Myers Co., Inc., Pharmaceutical Research and Development Division, 06492, Wallingford, CT, USA aut NATIONALLICENCE 700 1- Stringfellow Dale Bristol-Myers Co., Inc., Pharmaceutical Research and Development Division, 06492, Wallingford, CT, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/1(1990-02-01), 7-15 0167-6997 8:1<7 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer